secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-09-24T23:59:59+00:00
Accession:  0001437749-25-029768
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia regains Nasdaq compliance after raising $7.35M through equity offerings
--------------------------------------------------------------------------------

- Raised net proceeds of $0.7M (Apr), $0.5M (Jun), $5.1M (Sep public offer), and $1.0M from ATM sales (Apr–Sep 2025).
- Believes stockholders' equity now exceeds the $2.5M minimum for continued listing under Nasdaq Rule 5550(b)(1).
- Earlier Nasdaq extension to Sep 29, 2025; compliance will be monitored at next periodic report.
- Warrants exercisable earlier of 2030 or PMDA approval of CardiAMP Cell Therapy System.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925029768/0001437749-25-029768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925029768/bcda20250923_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-029768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer